Factor VIII in vitro bioequivalence of denecimig (Mim8) hemostatic effect by thrombin generation assays
Background: Denecimig (Mim8, Novo Nordisk A/S) is a next-generation bispecific antibody designed to mimic activated factor (F)VIII and restore hemostasis in persons with hemophilia A. The extent to which activated FVIII mimetics, such as denecimig and emicizumab, can correct clotting deficiency rema...
Bewaard in:
| Hoofdauteurs: | , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Elsevier
2026-01-01
|
| Reeks: | Research and Practice in Thrombosis and Haemostasis |
| Onderwerpen: | |
| Online toegang: | http://www.sciencedirect.com/science/article/pii/S2475037925006570 |
| Tags: |
Geen labels, Wees de eerste die dit record labelt!
|